Trials / Terminated
TerminatedNCT02156336
Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Horizons International Peripheral Group · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine if patients suffering from diabetic peripheral neuropathic pain treated with ranolazine will have a greater reduction in pain compared to placebo. Hypothesis: From the prior clinical observations, and analgesic efficacy in the preclinical animal model of neuropathic pain, the investigators hypothesize that subjects randomized to ranolazine will show a greater reduction in diabetic neuropathic pain compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranolazine | Oral administration, BID; for a maximum of 51 days. |
| DRUG | Placebo | Oral administration, BID; for a maximum of 51 days. |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2017-02-08
- Completion
- 2017-02-08
- First posted
- 2014-06-05
- Last updated
- 2017-02-10
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02156336. Inclusion in this directory is not an endorsement.